Inhibitors of the SDF-1 receptor CXCR4, such as AMD3100 (Plerixafor), prevent SDF-1/CXCL12-mediated recruitment of bone marrow-derived precursor cells to the tumor site [22,32]. This evidence concerns the gene CXCL12 and neoplasm.